Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus vaginal capsules are a live biotherapeutic product containing probiotic bacteria, most commonly *Lactobacillus delbrueckii* or *Lactobacillus acidophilus*. These capsules are administered intravaginally to restore and maintain a healthy vaginal microbiome, which is essential for preventing and treating urogenital infections. The mechanism of action involves the colonization of the vaginal mucosa by Lactobacilli, which produce lactic acid to maintain an acidic environment (pH < 4.5), hydrogen peroxide to inhibit anaerobic bacteria, and bacteriocins that directly target pathogens. In clinical practice, they are frequently used as an adjunct to standard antibiotics (like metronidazole) or antifungals (like fluconazole) to treat bacterial vaginosis and vulvovaginal candidiasis, reducing recurrence rates by re-establishing the protective microbial barrier. Recent research also explores their efficacy in promoting the clearance of high-risk human papillomavirus (HPV) infections by modulating local immune responses and microbial balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus vaginal capsules.